Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Marijke Peetermans, Charles Pollack$suffix/text()$suffix/text(), Paul Reilly, Laurens Liesenborghs, Marc Jacquemin, Jerrold H. Levy, Jeffrey I. Weitz & Peter Verhamme. (2016) Idarucizumab for dabigatran overdose. Clinical Toxicology 54:8, pages 644-646.
Read now
Read now
George Kimpton, Bassam Dabbous & Paul Leach. (2015) New oral anticoagulant and antiplatelet agents for neurosurgeons. British Journal of Neurosurgery 29:5, pages 614-621.
Read now
Read now
Articles from other publishers (29)
Orly Efros, Aya Berman, Gili Kenet, Aharon Lubetsky, Alon Doron, Gadi Shlomai, Eyal Klang, Shelly Soffer, Noam Barda & Avshalom Leibowitz. (2023) Elevated International Normalized Ratio and Mortality in Hospitalized Patients Treated with Direct Oral Anticoagulants. The American Journal of Medicine.
Crossref
Crossref
Sophia Pathan & Andrew T. Genco. (2022) Apixaban-Associated Intracranial Hemorrhage in a Patient With Elevated International Normalized Ratio. Journal of Pharmacy Practice, pages 089719002211441.
Crossref
Crossref
Adil Khan, Joshua Mastenbrook & Laura Bauler. (2020) Pain in the hip: Spontaneous retroperitoneal hemorrhage in an elderly patient on apixaban. The American Journal of Emergency Medicine 38:5, pages 1046.e1-1046.e3.
Crossref
Crossref
Cheralyn J. Hendrix, Lisbi Rivas & Babak Sarani. 2020. Evidence-Based Practice of Critical Care. Evidence-Based Practice of Critical Care
598
604.e1
.
V. М. Меretskyi & І. V. Меretska. (2019) Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications. Klinicheskaia khirurgiia 86:6, pages 73-76.
Crossref
Crossref
David M. Williams, Andrew Hodge, Joseph Catino, Charles DiMaggio, Gary Marshall, Patricia Ayoung-Chee, Spiros Frangos & Marko Bukur. (2018) Correlation of thromboelastography with conventional coagulation testing in elderly trauma patients on pre-existing blood thinning medications. The American Journal of Surgery 216:5, pages 874-880.
Crossref
Crossref
H. Paco Kang & Jay R. Lieberman. (2018) Venous thromboembolism after total joint arthroplasty: Risk stratification and prophylaxis. Seminars in Arthroplasty 29:3, pages 200-204.
Crossref
Crossref
Terese T. Horlocker, Erik Vandermeuelen, Sandra L. Kopp, Wiebke Gogarten, Lisa R. Leffert & Honorio T. Benzon. (2018) Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. Regional Anesthesia and Pain Medicine 43:3, pages 263-309.
Crossref
Crossref
J.W. Eikelboom, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z. Boda, F. Christory, I. Gornik, G. Kėkštas, A. Kher, R. Komadina, O. Koval, G. Mitic, T. Novikova, E. Pazvanska, S. Ratobilska, J. Sütt, A. Winder & D. Zateyshchikov. (2018) Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia 120:4, pages 645-656.
Crossref
Crossref
Claudia Stöllberger & Birke Schneider. (2017) Concerns about andexanet. Blood Coagulation & Fibrinolysis 28:4, pages 275.
Crossref
Crossref
Leslie Kobayashi, Galinos Barmparas, Patrick Bosarge, Carlos V. Brown, Marko Bukur, Matthew M. Carrick, Richard D. Catalano, Jan Holly-Nicolas, Kenji Inaba, Stephen Kaminski, Amanda L. Klein, Tammy Kopelman, Eric J. Ley, Ericca M. Martinez, Forrest O. Moore, Jason Murry, Raminder Nirula, Douglas Paul, Jacob Quick, Omar Rivera, Martin Schreiber & Raul Coimbra. (2017) Novel oral anticoagulants and trauma. Journal of Trauma and Acute Care Surgery 82:5, pages 827-835.
Crossref
Crossref
Fanny Ofek, Samuel Bar Chaim, Nirit Kronenfeld, Tomer Ziv-Baran & Matitiahu Berkovitch. (2017) International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study. Clinical Therapeutics 39:5, pages 1003-1010.
Crossref
Crossref
Lene Rosenberg, Gustav Gerstrøm & Mads Nybo. (2017) Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. Basic & Clinical Pharmacology & Toxicology 120:4, pages 407-410.
Crossref
Crossref
Masahiro Yasaka. 2017. Treatment of Non-vitamin K Antagonist Oral Anticoagulants. Treatment of Non-vitamin K Antagonist Oral Anticoagulants
25
39
.
James A. Reiffel, Jeffrey I. Weitz, Paul Reilly, Edvardas Kaminskas, Troy Sarich, Philip Sager & Jonathan Seltzer. (2016) NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American Heart Journal 177, pages 74-86.
Crossref
Crossref
Claudia Stöllberger, Peter Pommer, Birke Schneider & Josef Finsterer. (2016) Concerns about idarucizumab for dabigatran reversal. Blood Coagulation & Fibrinolysis 27:4, pages 473-474.
Crossref
Crossref
Maureen A. Smythe, Toby Trujillo & John Fanikos. (2016) Reversal agents for use with direct and indirect anticoagulants. American Journal of Health-System Pharmacy 73:10_Supplement_2, pages s27-s48.
Crossref
Crossref
Patricia Anne O’Malley. (2016) The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran. Clinical Nurse Specialist 30:2, pages 81-83.
Crossref
Crossref
Hiroyuki Hamada, Shinichi Wada, Yohei Mima, Masahiro Yasaka, Takahiro Kuwashiro & Yasushi Okada. (2016) A case of thalamic hemorrhage which occurred during anticoagulant therapy with Xa inhibitor and expanded even after the administration of prothrombin complex concentrate. Nosotchu 38:6, pages 413-417.
Crossref
Crossref
V. Koenig-Oberhuber & M. Filipovic. (2016) New antiplatelet drugs and new oral anticoagulants. British Journal of Anaesthesia 117, pages ii74-ii84.
Crossref
Crossref
Jeremy M. Bennett & Kara Siegrist. (2016) Evidence-Based Perioperative Management of Cardiac Medications in Patients Presenting for Noncardiac Surgery. Advances in Anesthesia 34:1, pages 161-180.
Crossref
Crossref
Alessandro Di Minno, Gaia Spadarella, Emanuela Spadarella, Elena Tremoli & Giovanni Di Minno. (2015) Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. Thrombosis Research 136:6, pages 1074-1081.
Crossref
Crossref
Luís Mont, Francisco Marín, Fernando García-Bragado Dalmau, Marianela Sánchez Martínez & Jaime Gallego Cullere. (2015) Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology 11:5, pages 565-583.
Crossref
Crossref
Charles André. (2015) Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery. Arquivos de Neuro-Psiquiatria 73:8, pages 704-713.
Crossref
Crossref
Betsy KarliBillie BartelRachel Pavelko. (2015) Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors. Hospital Pharmacy 50:7, pages 569-577.
Crossref
Crossref
Jenni Ilomäki, Arja Helin-Salmivaara, Risto Huupponen, Maria Rikala, Carl M. Kirkpatrick & Maarit Jaana Korhonen. (2015) Analgesic use before and after oral anticoagulant initiation—a population-based study in Finland. European Journal of Clinical Pharmacology 71:6, pages 723-732.
Crossref
Crossref
Anne R. Bass. (2015) Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery. Current Rheumatology Reports 17:4.
Crossref
Crossref
Arun Krishnamoorthy, Matthew W. Sherwood, Renato D. Lopes & Richard C. Becker. (2015) The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. American Heart Journal 169:3, pages 315-322.
Crossref
Crossref
Hiroyuki Hamada, Shinichi Wada, Yohei Mima, Masahiro Yasaka, Takahiro Kuwashiro & Yasushi Okada. (2015) Retraction:The onset of thalamic hemorrhage in Rivaroxaban in oral IX factor complex formulation administration, but showed a hematoma expansion case. Rinsho Shinkeigaku.
Crossref
Crossref